EGFR基因突变非小细胞肺癌药物治疗对心脏影响
Cardiac effects of drug therapy for non-small cell lung cancer with EGFR gene mutation
胡雅宁 1陈传军 1刘元生 2曲涛1
作者信息
- 1. 内蒙古包钢医院/内蒙古医科大学第三附属医院(014010)
- 2. 北京大学人民医院(100044)
- 折叠
摘要
非小细胞肺癌(Non-small-cell carcinoma,NSCLC)约占肺癌患者的85％,且发病率逐年增加,而分子靶向治疗的快速发展为晚期非小细胞肺癌的患者带来了希望.其中,表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗非小细胞肺癌期间不可避免地会出现不同程度的心血管毒性.临床上在治疗非小细胞肺癌的同时,关注EGFR-TKI所致的心血管毒性是必要的.本文就EGFR-TKI治疗晚期非小细胞肺癌所导致的心血管毒性做出分析,以探索基于免疫疗法抑制剂治疗EGFR-TKI耐药非小细胞肺癌患者的重要临床研究,为更好地治愈非小细胞肺癌,并防治相关并发症提供参考.
Abstract
Non-small cell lung cancer(NSCLC)accounts for about 85％of lung cancer patients,and the incidence is increasing year by year,while the rapid development of molecular targeted therapy has brought hope to patients with advanced non-small cell lung cancer.Among them,epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)in the treatment of non-small cell lung cancer will inevitably appear different degrees of cardiovascular toxicity.It is necessary to pay attention to the cardiovascular toxicity caused by EGFR-TKI in the treatment of non-small cell lung cancer.This paper analyzes the cardiovascular toxicity caused by EGFR-TKI in the treatment of advanced non-small cell lung cancer,and explores the important clinical studies based on immunotherapy inhibitors in the treatment of EGFR-TKI resistant NSCLC patients,so as to provide references for better cure of non-small cell lung cancer and prevention and treatment of related complications.
关键词
心血管毒性/表皮生长因子酪氨酸激酶抑制剂/非小细胞肺癌/肿瘤心脏病Key words
Cardiovascular toxicity/Epidermal growth factor tyrosine kinaseinhibitors/Non-small cell lung cancer/Tumor cardiology引用本文复制引用
出版年
2024
NETL
NSTL
万方数据